{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:01:58Z","timestamp":1757617318138,"version":"3.44.0"},"reference-count":48,"publisher":"Japan Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej25-0051","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T18:08:11Z","timestamp":1746209291000},"page":"967-978","source":"Crossref","is-referenced-by-count":0,"title":["Biased antibodies and beyond: a new era in the diagnosis of PTH-dependent hypercalcemia"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-115X","authenticated-orcid":false,"given":"Noriko","family":"Makita","sequence":"first","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo 113-8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Manaka","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo 113-8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo 113-8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Horikoshi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo 113-8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo 113-8655, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1844-0741","authenticated-orcid":false,"given":"Taroh","family":"Iiri","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo 113-8655, Japan"},{"name":"Department of Pharmacology, St. Marianna University School of Medicine, Kanagawa 217-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Renaghan AD, Rosner MH (2018) Hypercalcemia: etiology and management. Nephrol Dial Transplant 33: 549\u2013551.","DOI":"10.1093\/ndt\/gfy054"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Walker MD, Shane E (2022) Hypercalcemia: A Review. JAMA 328: 1624\u20131636.","DOI":"10.1001\/jama.2022.18331"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Tonon CR, Silva T, Pereira FWL, Queiroz DAR, Junior ELF, et al. (2022) A review of current clinical concepts in the pathophysiology, etiology, diagnosis, and management of hypercalcemia. Med Sci Monit 28: e935821.","DOI":"10.12659\/MSM.935821"},{"key":"4","unstructured":"4 Potts JT, J\u00fcppner H (2022) Disorders of the parathyroid gland and calcium homeostasis. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, <i>et al.<\/i> (eds) Harrison\u2019s principles of internal medicine (21st) McGraw-Hill Education, New York, USA: 3169\u20133190."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Motlaghzadeh Y, Bilezikian JP, Sellmeyer DE (2021) Rare causes of hypercalcemia: 2021 update. J Clin Endocrinol Metab 106: 3113\u20133128.","DOI":"10.1210\/clinem\/dgab504"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Lecoq AL, Livrozet M, Blanchard A, Kamenick\u00fd P (2021) Drug-related hypercalcemia. Endocrinol Metab Clin North Am 50: 743\u2013752.","DOI":"10.1016\/j.ecl.2021.08.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Mifsud S, Mifsud EL, Agius SM, Mula A, Gruppetta M (2022) Immobilisation hypercalcaemia. Br J Hosp Med (Lond) 83: 1\u20137.","DOI":"10.12968\/hmed.2021.0624"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Guise TA, Wysolmerski JJ (2022) Cancer-associated hypercalcemia. N Engl J Med 386: 1443\u20131451.","DOI":"10.1056\/NEJMcp2113128"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Foley TP Jr, Harrison HC, Arnaud CD, Harrison HE (1972) Familial benign hypercalcemia. J Pediatr 81: 1060\u20131067.","DOI":"10.1016\/S0022-3476(72)80232-4"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10 Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, et al. (1993) Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297\u20131303.","DOI":"10.1016\/0092-8674(93)90617-Y"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, et al. (2022) Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. J Bone Miner Res 37: 2293\u20132314.","DOI":"10.1002\/jbmr.4677"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Shinall MC Jr, Dahir KM, Broome JT (2013) Differentiating familial hypocalciuric hypercalcemia from primary hyperparathyroidism. Endocr Pract 19: 697\u2013702.","DOI":"10.4158\/EP12284.RA"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Arshad MF, McAllister J, Merchant A, Rab E, Cook J, et al. (2021) Urinary calcium indices in primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH): which test performs best? Postgrad Med J 97: 577\u2013582.","DOI":"10.1136\/postgradmedj-2020-137718"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, et al. (2008) Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf) 69: 713\u2013720.","DOI":"10.1111\/j.1365-2265.2008.03259.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Moore EC, Berber E, Jin J, Krishnamurthy V, Shin J, et al. (2018) Calcium-creatinine clearance ratio is not helpful in differentiating primary hyperparathyroidism from familial hypercalcemic hypocalciuria: a study of 1,000 patients. Endocr Pract 24: 988\u2013994.","DOI":"10.4158\/EP-2018-0350"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Song L, Liu L, Miller RT, Yan SX, Jackson N, et al. (2017) Glucocorticoid-responsive lymphocytic parathyroiditis and hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor: a case report and literature review. Eur J Endocrinol 177: K1\u2013K6.","DOI":"10.1530\/EJE-17-0172"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Attie MF, Gill JR Jr, Stock JL, Spiegel AM, Downs RW Jr, et al. (1983) Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism. J Clin Invest 72: 667\u2013676.","DOI":"10.1172\/JCI111016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Tsukamoto Y, Watanabe T, Nakagami T, Morishita K (2003) Effect of treatment with oral calcitriol on calcium metabolism and fasting serum 25(OH)- or 1,25(OH)2-vitamin D level in Japanese postmenopausal women. Endocr J 50: 681\u2013687.","DOI":"10.1507\/endocrj.50.681"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 De Sousa SMC, Carroll RW, Henderson A, Burgess J, Clifton-Bligh RJ (2022) A contemporary clinical approach to genetic testing for heritable hyperparathyroidism syndromes. Endocrine 75: 23\u201332.","DOI":"10.1007\/s12020-021-02927-3"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20 Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, et al. (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366: 575\u2013580.","DOI":"10.1038\/366575a0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Brown EM (2007) Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 3: 122\u2013133.","DOI":"10.1038\/ncpendmet0388"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Pallais JC, Kifor O, Chen YB, Slovik D, Brown EM (2004) Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Engl J Med 351: 362\u2013369.","DOI":"10.1056\/NEJMoa040008"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kifor O, Moore FD Jr, Delaney M, Garber J, Hendy GN, et al. (2003) A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab 88: 60\u201372.","DOI":"10.1210\/jc.2002-020249"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Makita N, Sato J, Manaka K, Shoji Y, Oishi A, et al. (2007) An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. Proc Natl Acad Sci U S A 104: 5443\u20135448.","DOI":"10.1073\/pnas.0701290104"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Makita N, Iiri T (2014) Biased agonism: a novel paradigm in G protein-coupled receptor signaling observed in acquired hypocalciuric hypercalcemia. Endocr J 61: 303\u2013309.","DOI":"10.1507\/endocrj.EJ13-0453"},{"key":"26","doi-asserted-by":"crossref","first-page":"e126449","DOI":"10.1172\/jci.insight.126449","volume":"4","author":"N Makita","year":"2019","unstructured":"26 Makita N, Ando T, Sato J, Manaka K, Mitani K, et al. (2019) Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody. JCI Insight 4: e126449.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"27","doi-asserted-by":"crossref","first-page":"e156742","DOI":"10.1172\/jci.insight.156742","volume":"7","author":"N Makita","year":"2022","unstructured":"27 Makita N, Sato J, Manaka K, Akahane K, Ito T, et al. (2022) Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies. JCI Insight 7: e156742.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Pallais JC, Kemp EH, Bergwitz C, Kantham L, Slovik DM, et al. (2011) Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor. J Clin Endocrinol Metab 96: 672\u2013680.","DOI":"10.1210\/jc.2010-1739"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, et al. (2004) Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 279: 18990\u201318997.","DOI":"10.1074\/jbc.M400724200"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Mi\u00f1ambres I, Corcoy R, Weetman AP, Kemp EH (2020) Autoimmune hypercalcemia due to autoantibodies against the calcium-sensing receptor. J Clin Endocrinol Metab 105: dgaa219.","DOI":"10.1210\/clinem\/dgaa219"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Kuo E, Kemp EH, Sandhu HK, Brown EM, Weetman AP, et al. (2013) Acquired hypocalciuric hypercalcemia in a patient with CKD. Am J Kidney Dis 62: 1151\u20131154.","DOI":"10.1053\/j.ajkd.2013.04.023"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Kifor O, McElduff A, LeBoff MS, Moore FD Jr, Butters R, et al. (2004) Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 89: 548\u2013556.","DOI":"10.1210\/jc.2003-031054"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Habibullah M, Porter JA, Kluger N, Ranki A, Krohn KJE, et al. (2018) Calcium-sensing Receptor Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1: epitopes, specificity, functional affinity, IgG subclass, and effects on receptor activity. J Immunol 201: 3175\u20133183.","DOI":"10.4049\/jimmunol.1701527"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Dadu R, Rodgers TE, Trinh VA, Kemp EH, Cubb TD, et al. (2020) Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. J Immunother Cancer 8: e000687.","DOI":"10.1136\/jitc-2020-000687"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Lupi I, Brancatella A, Cetani F, Latrofa F, Kemp EH, et al. (2020) Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism. J Clin Endocrinol Metab 105: dgaa092.","DOI":"10.1210\/clinem\/dgaa092"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Sanada J, Kamei S, Shimoda M, Tatsumi F, Kimura T, et al. (2021) Amelioration of hypercalcemia by cinacalcet treatment in a subject with relapsing acquired hypocalciuric hypercalcemia: a case report. Medicine (Baltimore) 100: e27579.","DOI":"10.1097\/MD.0000000000027579"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Conklin BR, Bourne HR (1994) Homeostatic signals. Marriage of the flytrap and the serpent. Nature 367: 22.","DOI":"10.1038\/367022a0"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Lee JY, Shoback DM (2018) Familial hypocalciuric hypercalcemia and related disorders. Best Pract Res Clin Endocrinol Metab 32: 609\u2013619.","DOI":"10.1016\/j.beem.2018.05.004"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Wettschureck N, Lee E, Libutti SK, Offermanns S, Robey PG, et al. (2007) Parathyroid-specific double knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of the extracellular Ca2+ -sensing receptor. Mol Endocrinol 21: 274\u2013280.","DOI":"10.1210\/me.2006-0110"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, et al. (2013) Mutations affecting G-protein subunit \u03b111 in hypercalcemia and hypocalcemia. N Engl J Med 368: 2476\u20132486.","DOI":"10.1056\/NEJMoa1300253"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 He F, Wu CG, Gao Y, Rahman SN, Zaoralov\u00e1 M, et al. (2024) Allosteric modulation and G-protein selectivity of the Ca(2+)-sensing receptor. Nature 626: 1141\u20131148.","DOI":"10.1038\/s41586-024-07055-2"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Riccardi D, Valenti G (2016) Localization and function of the renal calcium-sensing receptor. Nat Rev Nephrol 12: 414\u2013425.","DOI":"10.1038\/nrneph.2016.59"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Atila C, Loughrey PB, Garrahy A, Winzeler B, Refardt J, et al. (2022) Central diabetes insipidus from a patient\u2019s perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Lancet Diabetes Endocrinol 10: 700\u2013709.","DOI":"10.1016\/S2213-8587(22)00219-4"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Arima H, Cheetham T, Christ-Crain M, Cooper D, Gurnell M, et al. (2022) Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus. Endocr J 69: 1281\u20131284.","DOI":"10.1507\/endocrj.EJ20220831"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Levi M, Ellis MA, Berl T (1983) Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Invest 71: 1624\u20131632.","DOI":"10.1172\/JCI110918"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T (1996) Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 19: 31\u201336.","DOI":"10.1291\/hypres.19.31"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Sutton RA (1970) Plasma magnesium concentration in primary hyperparathyroidism. Br Med J 1: 529\u2013533.","DOI":"10.1136\/bmj.1.5695.529"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Firek AF, Kao PC, Heath H 3rd (1991) Plasma intact parathyroid hormone (PTH) and PTH-related peptide in familial benign hypercalcemia: greater responsiveness to endogenous PTH than in primary hyperparathyroidism. J Clin Endocrinol Metab 72: 541\u2013546.","DOI":"10.1210\/jcem-72-3-541"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/9\/72_EJ25-0051\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:32:40Z","timestamp":1757129560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/9\/72_EJ25-0051\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0051","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"type":"print","value":"0918-8959"},{"type":"electronic","value":"1348-4540"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ25-0051"}}